Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017

JAMA network open- United States

doi 10.1001/jamanetworkopen.2020.3284

Full Text

Abstract

Available in

Categories

Date

April 21, 2020

Authors

Audrey D. Zhang

Jeremy Puthumana

Nicholas S. Downing

Harlan M. Krumholz

Publisher

American Medical Association (AMA)

Related search

Transparency and Dermatologic Device Approval by the US Food and Drug Administration

JAMA Dermatology

English

Have Thoracic Endografting Outcomes Improved Since US Food and Drug Administration Approval?

Annals of Thoracic Surgery

Respiratory Medicine

Cardiovascular Medicine

English

Inclusion of Training Patients in US Food and Drug Administration Premarket Approval Cardiovascular Device Studies

Archives of Internal Medicine

English

S18 Longitudinal Assessment of Biomarkers for Clinical Trials of Novel Therapeutic Agents: The Run-In Study

Respiratory Medicine

English

Magnitude and Pattern of Placebo Response in Clinical Trials of Oral Antihyperglycemic Agents: Data From the Food and Drug Administration 1999–2015

Internal Medicine

Specialized Nursing

English

New Drug Approval Probability Model in Phased Clinical Trials

American Journal of Health Research

English

Analysis of Benefit-Risk Balance in Decision-Making of the Food and Drug Administration for Premarket Approval of Therapeutic Medical Devices

Advanced Biomedical Engineering

Pattern Recognition

Computer Vision

Computer Science Applications

Biomedical Engineering

English

The Clinical Pharmacogeneticist: An Emerging Regulatory Scientist at the US Food and Drug Administration

Molecular Medicine

Molecular Biology

English

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration

JAMA network open

English